AWA
RXRX icon

Arkadios Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Arkadios Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$50.6K – 1510
2025
Q2 		$50.6K Buy
+10,000
New +$49.1K ﹤0.01% 1286

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arkadios Wealth Advisors's RXRX Position: Q1 2026 in Review

Arkadios Wealth Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 9.4% in Q1 2026, selling an estimated $14K and leaving 35,206 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #1616.

Arkadios Wealth Advisors first reported a position in RXRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $222K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Arkadios Wealth Advisors held 35,206 shares of Recursion Pharmaceuticals worth $108K as of Q1 2026.
  • Arkadios Wealth Advisors sold 3,634 Recursion Pharmaceuticals shares in Q1 2026, an estimated $14K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Arkadios Wealth Advisors's portfolio in Q1 2026, its #1616 holding.
  • Arkadios Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Arkadios Wealth Advisors's Recursion Pharmaceuticals position peaked at $222K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.